Teva launches Qvar RediHaler
Teva has introduced its Qvar RediHaler, a breath-actuated aerosol inhaled corticosteroid that the company said is the first of its kind. The product, which Teva said eliminates the need for hand-breath coordination, is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients ages four years and older.
“Qvar has been an available asthma treatment option for well over a decade, so we are excited by the new technology of Qvar RediHaler that directly addresses an unmet need in the field of asthma management,” Teva executive vice president of North American commercial Brendan O’Grady said. “By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of Qvar RediHaler in the coming months.”
The product, which the Food and Drug Administration approved in August 2017, will replace the now-discontinued QVAR. Teva said Qvar RediHaler is designed to be ready to use without priming or shaking and without a spacer or volume-holding chamber. The company said that if desired, the new product will be priced at parity to Qvar.
“Qvar has been an available asthma treatment option for well over a decade, so we are excited by the new technology of Qvar RediHaler that directly addresses an unmet need in the field of asthma management,” Teva executive vice president of North American commercial Brendan O’Grady said. “By merging our breath-actuated inhaler technology with asthma medication, we hope to better serve the needs of the respiratory community and look forward to seeing the adoption of Qvar RediHaler in the coming months.”
The product, which the Food and Drug Administration approved in August 2017, will replace the now-discontinued QVAR. Teva said Qvar RediHaler is designed to be ready to use without priming or shaking and without a spacer or volume-holding chamber. The company said that if desired, the new product will be priced at parity to Qvar.